14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
×
Home
/
Stock Analysis
/
Compare Terminal
/
MYGN vs XOMA
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
MYGN vs XOMA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
XOMA Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 9–1 Matrix Metrics)
XOMA Overall Winner
6-Pillar Tally: MYGN 3 – 3 XOMA
Matrix Metrics: MYGN 1 – 9 XOMA
As of Nov 16, 2026, XOMA Royalty Corporation (XOMA) is the stronger overall head-to-head candidate over Myriad Genetics Inc (MYGN) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). MYGN carries a Unified Composite Score of 45.9/100 (HOLD) at $5.62 (54.0x Forward P/E, -13.3% operating margin), whereas XOMA carries 55.8/100 (HOLD) at $40.17 (21.5x Forward P/E, -3.9% operating margin).
Growth vs. Quality Trade-Off: XOMA earns the overall head-to-head edge with a stronger Unified Composite Score (55.8/100 HOLD vs. MYGN 45.9/100 HOLD) and 0.68β · 37% Vol risk profile, whereas MYGN leads top-line expansion (-1.5% YoY revenue growth, 1.40x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
MYGN
NASDAQ
Myriad Genetics Inc
In Vitro & In Vivo Diagnostic Substances
Market Cap
$544.8M
TTM Revenue
$804M
Forward P/E
54.0x
Beta / 30D Vol
0.69β · 122% Vol
Unified Composite Score
45.9 / 100
HOLD
Tech 30.0
Fund 41.0
Flow 56.0
Mom 50.0
Weinstein Technical Phase
Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (30.2% over 20 days), RSI 52
RSI-14: 52.0 · SMA20: $5.94 · SMA50: $4.80
XOMA
NASDAQ
Head-to-Head Winner
XOMA Royalty Corporation Common Stock
Pharmaceutical Preparations
Market Cap
$781.8M
TTM Revenue
$49M
Forward P/E
21.5x
Beta / 30D Vol
0.68β · 37% Vol
Unified Composite Score
55.8 / 100
HOLD
Tech 40.0
Fund 52.0
Flow 50.0
Mom 64.0
Weinstein Technical Phase
Neutral · Hold
Mixed signals - no dominant trend phase, RSI 35
RSI-14: 34.5 · SMA20: $42.59 · SMA50: $42.06
6-Pillar Scorecard Institutional Category Breakdown (MYGN 3 – 3 XOMA)
Columns: Metric · MYGN · XOMA
1. Valuation Multiples
XOMA
Forward P/E
54.0x
21.5x
Trailing P/E
54.0x
28.2x
PEG Ratio
1.40x
N/M
EV / Revenue
0.8x
16.1x
2. Growth & Scale
MYGN
Revenue Growth (YoY)
-1.5%
-22.6%
Earnings Growth (YoY)
+0.0%
+207.9%
TTM Revenue (USD)
$804M
$49M
Market Cap
$544.8M
$781.8M
3. Profitability & Quality
XOMA
Gross Margin
68.3%
99.0%
Operating Margin
-13.3%
-3.9%
Net Profit Margin
-16.1%
69.6%
Return on Equity (ROE)
-40.2%
34.2%
4. Balance Sheet & Cash Flow
XOMA
Cash Generation (TTM)
-$38M
$8.3M EBITDA
Cash Flow Margin
-4.7%
17.1% EBITDA Mgn
Net Cash / Leverage
$102M Net Debt (0.78x D/E)
$7.79 Book/Sh · 34.2% ROE
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
MYGN
Options Structure Phase
SURGE
UNCLASSIFIED
Current IV / %ile
124.6% (22nd %ile)
101.5% (100th %ile)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
DISTRIBUTION · Markup
NEUTRAL · Neutral
6. R&D & Supply-Chain Moat
MYGN
OpEx & R&D Intensity
81.6% of Rev ($656M)
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Scale & Operating Efficiency Moat
Supply-Chain Role
Diagnostics & Research Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: MYGN (1) vs XOMA (9)
Institutional Metric
MYGN
XOMA
Criterion
Row Edge
Market Capitalization
Scale
$544.8M
$781.8M
Larger Scale
XOMA
Trailing P/E Ratio
Valuation
54.0x
28.2x
Lower Multiple
XOMA
Forward P/E Ratio
Valuation
54.0x
21.5x
Lower Multiple
XOMA
Revenue Growth (YoY)
Growth
-1.5%
-22.6%
Higher Growth
MYGN
Operating Margin (TTM)
Profitability
-13.3%
-3.9%
Higher Margin
XOMA
Net Profit Margin
Profitability
-16.1%
69.6%
Higher Margin
XOMA
Return on Equity (ROE)
Capital Efficiency
-40.2%
34.2%
Higher ROE
XOMA
52-Week Range Position
Momentum
54% ($3–$8)
78% ($22–$45)
Stronger Trend
XOMA
Beta / 30D Volatility
Risk Regime
0.69β · 122% Vol
0.68β · 37% Vol
Lower Realized Risk
XOMA
Unified Institutional Score
Composite Signal
45.9 / 100 (HOLD)
55.8 / 100 (HOLD)
Higher Composite
XOMA
Trailing 12M Revenue (USD)
Operating Scale
$804M
$49M
FX-Normalized USD
Scale
Gross Profit Margin (TTM)
Unit Pricing Power
68.3%
99.0%
Higher Margin
Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.40x PEG · 0.8x EV/Rev
N/M PEG · 16.1x EV/Rev
Lower Multiple
Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$38M ($102M Net Debt (0.78x D/E))
$8.3M EBITDA ($7.79 Book/Sh · 34.2% ROE)
Higher Cash / Net Cash
Solvency
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M
3M
6M
1Y
1M Horizon
MYGN +36.09 pp
MYGN:
+32.28%
·
XOMA:
-3.81%
3M Horizon
MYGN +25.37 pp
MYGN:
+34.71%
·
XOMA:
+9.34%
6M Horizon
XOMA +44.93 pp
MYGN:
-10.67%
·
XOMA:
+34.26%
1Y Horizon
XOMA +32.32 pp
MYGN:
-7.72%
·
XOMA:
+24.6%
Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)
Split-Invariant USD Revenue & Operating Margin (%)
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MYGN vs XOMA. Trailing 12-month operating profitability (MYGN -13.3% vs XOMA -3.9%) and valuation multiples (MYGN 54.0x vs XOMA 21.5x Forward P/E) are benchmarked directly in Pillar 4 below.
MYGN ADR TTM Benchmark
FX-Normalized USD
TTM Revenue $804M
Gross Margin 68.3%
Op. Margin -13.3%
ROE / Fwd P/E -40.2% · 54.0x
XOMA ADR TTM Benchmark
FX-Normalized USD
TTM Revenue $49M
Gross Margin 99.0%
Op. Margin -3.9%
ROE / Fwd P/E 34.2% · 21.5x
MYGN
SURGE
12d in phase · OBV DISTRIBUTION
Current IV
124.6%
IV Percentile
22nd %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
DISTRIBUTION
XOMA
UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV
101.5%
IV Percentile
100th %ile
Put/Call OI Skew
N/A
IV Regime
Extreme (>80th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
MYGN Moat Profile
Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $544.8M market capitalization and -13.3% operating margin.
OpEx & R&D Reinvestment
81.6% of Rev ($656M)
90D Engineering Disclosures
0 Published
XOMA Moat Profile
Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $781.8M market capitalization and -3.9% operating margin.
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ MYGN vs XOMA Key Questions & Quantitative Answers
Is MYGN or XOMA a better stock to buy right now?
As of Nov 16, 2026, XOMA Royalty Corporation (XOMA) is the stronger overall head-to-head candidate over Myriad Genetics Inc (MYGN) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). MYGN carries a Unified Composite Score of 45.9/100 (HOLD) at $5.62 (54.0x Forward P/E, -13.3% operating margin), whereas XOMA carries 55.8/100 (HOLD) at $40.17 (21.5x Forward P/E, -3.9% operating margin). Growth vs. Quality Trade-Off: XOMA earns the overall head-to-head edge with a stronger Unified Composite Score (55.8/100 HOLD vs. MYGN 45.9/100 HOLD) and 0.68β · 37% Vol risk profile, whereas MYGN leads top-line expansion (-1.5% YoY revenue growth, 1.40x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
Does MYGN or XOMA have stronger revenue and earnings growth?
MYGN leads the Growth & Scale pillar: MYGN posts -1.5% YoY revenue growth and +0.0% YoY earnings growth on $804M TTM revenue (68.3% gross margin, -13.3% operating margin), compared with XOMA at -22.6% YoY revenue growth and +207.9% YoY earnings growth on $49M TTM revenue (99.0% gross margin, -3.9% operating margin). On trailing 12-month operating scale, MYGN generates $804M in USD-normalized revenue versus $49M for XOMA. In operating R&D and SG&A reinvestment, MYGN deploys 81.6% of Rev ($656M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for XOMA.
Is MYGN or XOMA cheaper on valuation?
XOMA screens cheaper on headline valuation multiples. MYGN trades at 54.0x Forward P/E, 54.0x Trailing P/E, 1.40x PEG, and 0.8x EV/Revenue (-4.7% FCF margin), whereas XOMA trades at 21.5x Forward P/E, 28.2x Trailing P/E, N/M PEG, and 16.1x EV/Revenue (17.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MYGN (-40.2% ROE) versus XOMA (34.2% ROE) capital efficiency.
How is options market volatility positioned on MYGN vs XOMA?
In options market volatility and institutional positioning, MYGN carries 124.6% implied volatility (22nd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.69β · 122% Vol realized risk). By comparison, XOMA carries 101.5% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.68β · 37% Vol realized risk).
Myriad Genetics Inc (MYGN) Research Suite
XOMA Royalty Corporation Common Stock (XOMA) Research Suite
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.